



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : C07D 213/85, A61K 31/44	A1	(11) International Publication Number: <b>WO 00/47561</b> (43) International Publication Date: 17 August 2000 (17.08.00)
--	----	---

(21) International Application Number: PCT/SE99/01403

(22) International Filing Date: 18 August 1999 (18.08.99)

## (30) Priority Data:

09/249,317	12 February 1999 (12.02.99)	US
PCT/SE99/00194	15 February 1999 (15.02.99)	SE

## (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US	09/249,317 (CIP)
Filed on	12 February 1999 (12.02.99)

(71) Applicant (for all designated States except US): MEDIVIR AB [SE/SE]; Lunastigen 7, S-141 44 Huddinge (SE).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): ZHOU, Xiao-Xiong [SE/SE]; Kallkärsvägen 12, S-141 41 Huddinge (SE). JOHANSSON, Nils-Gunnar [SE/SE]; Bäverstigen 19, S-150 23 Enhörna (SE). WÄHLING, Horst [DE/SE]; Tempelriddarevägen 3, S-127 61 Skärholmen (SE). SUND, Christian [FI/SE]; Bäckgårdsvägen, S-143 21 Värby (SE). SALVADOR, Lourdes [PH/SE]; Saltängsgatan 1B, S-602 22 Nörrköping (SE). LINDSTRÖM, Stefan [SE/SE];

Marmorsvägen, S-752 44 Uppsala (SE). WALLBERG, Hans [SE/SE]; Mangårdsvägen 10, S-141 51 Huddinge (SE). SAHLBERG, Christer [SE/SE]; Mälarhöjdsvägen 5L, S-129 40 Hägersten (SE).


(74) Agent: MORRISON, Iain; Medivir AB, Lunastigen 7, S-141 44 Huddinge (SE).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published

With international search report.

## (54) Title: NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS



## (57) Abstract

Non-nucleoside reverse transcriptase inhibitors of formula (P-1) wherein: Ar1 is an unsaturated, optionally substituted, mono or bicyclic ring structure comprising 0 to 3 hetero atoms selected from S, O and N; Ar2 is an aromatic, optionally substituted, monocyclic ring structure comprising at least one nitrogen hetero atom and zero to two further hetero atoms selected from S, O and N; R4 and R5 are independently H or C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>8</sub> alkynyl, C<sub>1</sub>-C<sub>5</sub> alkoxy, C<sub>1</sub>-C<sub>4</sub> alkanoyloxy, C<sub>1</sub>-C<sub>4</sub> alkylthio, amino, carboxy, carbamoyl, cyano, halo, hydroxy, aminomethyl, hydroxymethyl, carboxymethyl, or halo substituted C<sub>1</sub>-C<sub>6</sub> alkyl mercapto, nitro; or R4 and R5 join to form a 3-6 membered, optionally substituted ring structure; R6 is O or S; Rx is the residue of a natural or unnatural amino acid; and L\* is a linker moiety which is ether-, carbonate- or ester-bound to the adjacent oxygen and ester linked to Rx; and pharmaceutically acceptable salts thereof are anti-HIV agents with favourable pharmacokinetic properties.